About Quanterix
Quanterix is a company based in Cambridge (United States) founded in 2007. Quanterix has raised $99.5 million across 15 funding rounds from investors including General Electric, T. Rowe Price and Hercules Capital. The company has 471 employees as of December 31, 2024. Quanterix has completed 2 acquisitions, including Akoya Biosciences and UmanDiagnostics. Quanterix offers products and services including Simoa Assay Kits, Simoa HD-X Analyzer, and Custom Assay Development. Quanterix operates in a competitive market with competitors including Bio Rad, Horizon Discovery, Siemens Healthineers, Merck and Arrakis Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 471 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Quanterix Corporation
-
Annual Revenue
$137.42 M (USD)12.3as on Dec 31, 2024
-
Net Profit
-$38.53 M (USD)-35.89as on Dec 31, 2024
-
EBITDA
-$44.26 M (USD)-35.51as on Dec 31, 2024
-
Total Equity Funding
$99.5 M (USD)
in 15 rounds
-
Latest Funding Round
Not available
-
Investors
General Electric
& 13 more
-
Employee Count
471
as on Dec 31, 2024
-
Investments & Acquisitions
Akoya Biosciences
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Quanterix
Quanterix is a publicly listed company on the NASDAQ with ticker symbol QTRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Quanterix
Quanterix offers a comprehensive portfolio of products and services, including Simoa Assay Kits, Simoa HD-X Analyzer, and Custom Assay Development.
Kits for ultrasensitive protein biomarker measurement in research.
Automated platform for precise immunoassay detection.
Tailored solutions for specialized biomarker research needs.
People of Quanterix
Unlock access to complete
Unlock access to complete
Leadership Team
26 people
Senior Team
8 people
Finance and Accounting
6 people
Sales and Marketing
6 people
Product Management Team
5 people
Human Resources and Administration
3 people
Operations Team
2 people
Software Development Team
2 people
Unlock access to complete
Funding Insights of Quanterix
Quanterix has successfully raised a total of $99.5M across 15 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Quanterix
Quanterix has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include General Electric, T. Rowe Price and Hercules Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Venture capital fund focused on investing in multiple sectors
|
Locked | Locked | Locked | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked |
Investor details for Quanterix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Quanterix
Quanterix has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Akoya Biosciences and UmanDiagnostics.
Investment portfolio details for Quanterix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of solutions for rapid proteomic profiling
|
Locked | Locked | 2015 | Locked | |
|
Rapid ELISA tests for MS, ALS, and PD are developed.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Quanterix
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Quanterix
Detailed financials for Quanterix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Quanterix Comparisons
Peer comparison for Quanterix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Quanterix
Quanterix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bio Rad, Horizon Discovery, Siemens Healthineers, Merck and Arrakis Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Portfolio of products and services for life science research and clinical diagnostic markets
|
|
| Locked | Locked | Locked |
Genetically modified cell lines are developed using AAV gene-editing platform.
|
|
| Locked | Locked | Locked |
AI-based medical diagnostics are developed for healthcare applications.
|
|
| Locked | Locked | Locked |
Merck is engaged in science and technology solutions globally.
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
Detailed competitors of Quanterix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Quanterix
Complete news archive for Quanterix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Quanterix
Quanterix was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Quanterix is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Quanterix is a funded company, having raised a total of $99.5M across 15 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Quanterix is 471.
Annual revenue of Quanterix is $137.42M as on Dec 31, 2024.
Quanterix was founded in 2007 in Cambridge, United States, and operates in the biotechnology sector. Assay kits utilizing the Simoa technology are provided for ultra-sensitive biomarker detection. This solution supports research applications across oncology, neurology, cardiology, inflammation, and infectious diseases. Operations focus on enabling disease detection, prognosis, and treatment methods through precise biomarker analysis.
Quanterix's top competitors include Horizon Discovery, Biocare Medical and NanoString.
Quanterix offers Simoa Assay Kits, Simoa HD-X Analyzer, and Custom Assay Development.
Yes, Quanterix is publicly traded on NASDAQ under the ticker symbol QTRX.
Quanterix has made 2 acquisitions, including Akoya Biosciences, and UmanDiagnostics.
Quanterix has 14 investors. Key investors include General Electric, T. Rowe Price, Hercules Capital, HHS, and NFL.
The ticker symbol of Quanterix is QTRX on NASDAQ.